|
From Mild to Serious, Common to Rare: The Adverse Events of Osteoporosis Drugs
|
A market analysis shows that bisphosphonates will reach $14 billion in sales by 2021. As more patients are prescribed these osteoporosis drugs, physicians will increasingly be faced with managing drug-related adverse events. Learn more in this article.
|
|
Read more
|
|
|
|
A Review of Bisphosphonates for Osteoporosis
|
|
Evidence-based medicine and patient input needed in prescribing bisphosphonates for osteoporosis.
|
|
Read more
|
